MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer.

Tsao MS; Sholl L; Shiller M; Illei P; Wistuba II; Beasley MB; Schalper KA; Simmons A; Ansell P; Beruti S; Mino-Kenudson M

doi:10.1038/s41698-025-01144-9

← 뒤로

MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer.

1/5 보강

NPJ precision oncology 📖 저널 OA 89% 2025 Vol.9(1) p. 369

Tsao MS, Sholl L, Shiller M, Illei P, Wistuba II, Beasley MB, Schalper KA, Simmons A, Ansell P, Beruti S, Mino-Kenudson M

📖 무료 전문 🟢 PMC 전문 PMC12635195

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

MET protein (also known as c-Met protein) overexpression (OE) is an emerging clinically relevant biomarker that is targetable with antibody-drug conjugates.

이 논문을 인용하기

↓ .bib ↓ .ris

APA Tsao MS, Sholl L, et al. (2025). MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer.. NPJ precision oncology, 9(1), 369. https://doi.org/10.1038/s41698-025-01144-9

MLA Tsao MS, et al.. "MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer.." NPJ precision oncology, vol. 9, no. 1, 2025, pp. 369.

PMID 41266553

DOI 10.1038/s41698-025-01144-9

Abstract

MET protein (also known as c-Met protein) overexpression (OE) is an emerging clinically relevant biomarker that is targetable with antibody-drug conjugates. c-Met protein's prevalence varies, depending on the different OE thresholds, antibodies, and detection methodologies used. Unlike MET genomic aberrations, MET protein OE is a protein biomarker requiring immunohistochemistry (IHC)-based testing. Herein, we summarize the current evidence on MET protein OE, including prognostic value, heterogeneity, and stability. We also provide key considerations for enabling optimal real-world testing of this IHC-based biomarker.